Stem Cell Transplantation

High-dose acyclovir may reduce cytomegalovirus infection risk

Published in Blood Weekly, July 17th, 2003

High-dose prophylactic treatment with acyclovir may reduce the cytomegalovirus infection risk in stem cell transplant recipients.

"To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation," researchers in the United States performed a study involving "51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients."

"A total of 12 recipients were at moderate risk for CMV disease," while 39 patients "were at high risk," noted A. Verma and coauthors at the University of Chicago.

"Conditioning regimens varied, but GvHD [graft-versus-host disease] prophylaxis consisted of tacrolimus...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry